These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17030649)

  • 1. Natalizumab and immune cells.
    McFarland HF; Jacobson S
    Arch Neurol; 2006 Oct; 63(10):1366-7. PubMed ID: 17030649
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to "'Thinking without thinking' about natalizumab and PML".
    Houff S; Berger JR
    J Neurol Sci; 2008 Jan; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
    [No Abstract]   [Full Text] [Related]  

  • 3. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.
    Aly L; Yousef S; Schippling S; Jelcic I; Breiden P; Matschke J; Schulz R; Bofill-Mas S; Jones L; Demina V; Linnebank M; Ogg G; Girones R; Weber T; Sospedra M; Martin R
    Brain; 2011 Sep; 134(Pt 9):2687-702. PubMed ID: 21908874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab for relapsing multiple sclerosis.
    Meyer MA
    N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742009
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
    Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
    Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA.
    Tyler KL; Khalili K
    Rev Neurol Dis; 2005; 2(3):144-9. PubMed ID: 16400315
    [No Abstract]   [Full Text] [Related]  

  • 8. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
    Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
    Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Warnke C; Adams O; Kieseier BC
    N Engl J Med; 2009 Dec; 361(25):2489; author reply 2489-90. PubMed ID: 20050216
    [No Abstract]   [Full Text] [Related]  

  • 10. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
    N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune surveillance in multiple sclerosis patients treated with natalizumab.
    Stüve O; Marra CM; Jerome KR; Cook L; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Hemmer B; Monson NL; Racke MK
    Ann Neurol; 2006 May; 59(5):743-7. PubMed ID: 16634029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
    Planas R; Jelčić I; Schippling S; Martin R; Sospedra M
    Eur J Immunol; 2012 Mar; 42(3):790-8. PubMed ID: 22144343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.
    Warnke C; Smolianov V; Dehmel T; Andrée M; Hengel H; Zohren F; Arendt G; Wiendl H; Haas R; Hartung HP; Adams O; Kieseier BC
    Mult Scler; 2011 Feb; 17(2):151-6. PubMed ID: 21078695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive multifocal leukoencephalopathy.
    Berger JR
    Curr Neurol Neurosci Rep; 2007 Nov; 7(6):461-9. PubMed ID: 17999891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab and progressive multifocal leukoencephalopathy.
    Adelman B; Sandrock A; Panzara MA
    N Engl J Med; 2005 Jul; 353(4):432-3. PubMed ID: 15947083
    [No Abstract]   [Full Text] [Related]  

  • 16. Reemergence of PML in natalizumab-treated patients--new cases, same concerns.
    Major EO
    N Engl J Med; 2009 Sep; 361(11):1041-3. PubMed ID: 19741226
    [No Abstract]   [Full Text] [Related]  

  • 17. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.
    Berger JR; Koralnik IJ
    N Engl J Med; 2005 Jul; 353(4):414-6. PubMed ID: 15947082
    [No Abstract]   [Full Text] [Related]  

  • 18. Natalizumab: bound to rebound?
    Schiess N; Calabresi PA
    Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
    [No Abstract]   [Full Text] [Related]  

  • 19. Natalizumab for relapsing multiple sclerosis.
    Jeffery DR
    N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742008
    [No Abstract]   [Full Text] [Related]  

  • 20. JCV-specific CD4 T cell response: another piece of the puzzle in explaining some aspects of AIDS associated PML.
    Berger JR
    AIDS; 2003 Jul; 17(10):1557-9. PubMed ID: 12824794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.